TheProfitWatch

SCLX - Scilex Holding Company Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
14.5 -0.84 (-5.78%) --- --- --- 0.0 (0.0%) -0.35 (-2.37%) 0.07 (0.49%) 0.07 (0.49%)

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Closed

Earnings & Ratios

Basic EPS:
-2.26
Diluted EPS:
-2.26
Basic P/E:
-6.0453
Diluted P/E:
-6.0453
RSI(14) 1m:
9.38
VWAP:
13.66
RVol:
0.5979

Events

Period Kind Movement Occurred At
1m Price decrease 1m 13.94 -0.16 (-1.13%) Oct 15 12:39
1m Price decrease 1m 14.18 -0.22 (-1.53%) Oct 15 11:48
1m Price decrease 1m 14.61 -0.19 (-1.28%) Oct 15 11:12
10m Price increase 10m 15.07 +0.48 (+3.33%) Oct 15 09:39

Related News

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex’s CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica

Aug 21, 2025 10:00